ClinicalTrials.Veeva

Menu

PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

C

CSPC Pharmaceutical Group

Status and phase

Completed
Phase 4

Conditions

Lymphoma

Treatments

Drug: PEG-rhG-CSF

Study type

Interventional

Funder types

Industry

Identifiers

NCT02805218
CSPC-PGC-IV-02-1

Details and patient eligibility

About

The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.

Enrollment

410 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with age ≥ 18 years
  • diagnosis of lymphoma(Hodgkin's lymphoma and non-Hodgkin's lymphoma) patients
  • Karnofsky Performance Status Z70
  • life expectancy of at least 8 months
  • normal white blood cell count and platelet count
  • Written informed consent are acquired

Exclusion criteria

  • uncontrolled infection
  • pregnancy
  • Have accepted any other anti-tumor drug within 4 weeks before anticipated the study
  • Other situations that investigators consider as contra-indication for this study

Trial design

Primary purpose

Prevention

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

410 participants in 1 patient group

PEG-rhG-CSF
Experimental group
Description:
patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
Treatment:
Drug: PEG-rhG-CSF

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems